J&J’s Mark Graham on advancing nipocalimab as treatment for SLE
J&J EMEA Immunology therapeutic area head Mark Graham tells Srivani Venna that based on positive data from the Phase II…
J&J EMEA Immunology therapeutic area head Mark Graham tells Srivani Venna that based on positive data from the Phase II…